Results 231 to 240 of about 96,616 (241)

Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series

Multiple Sclerosis and Related Disorders, 2020
Vasilios Kimiskidis, Efrosini Papadaki, Konstantinos Notas   +2 more
exaly  

Therapy of highly active pediatric multiple sclerosis

Multiple Sclerosis Journal, 2019
Kevin Rostasy, David Ellenberger, Wolfgang Bruck   +2 more
exaly  

Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England

Journal of Medical Economics, 2015
Stephen Montgomery, Nicholas Adlard
exaly  

Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility

Journal of Medical Economics, 2017
Stephen Montgomery, Richard Nicholas, Nicholas Adlard   +2 more
exaly  

How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?

Frontiers in Neurology, 2013
Samuel Komoly, Larysa Sokolova, Ivan Milanov   +2 more
exaly  

Loss of Suppressor T Cells in Active Multiple Sclerosis

New England Journal of Medicine, 1980
Stephen L Hauser, Howard Weiner, Ellis Reinherz   +2 more
exaly  

NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab

Multiple Sclerosis and Related Disorders
Irène Schiavetti, Roberta Fantozzi, Livia Pasquali   +2 more
exaly  

Defining highly active multiple sclerosis: Survey bias and the interpretation of clinical definitions

Multiple Sclerosis and Related Disorders
openaire   +2 more sources

Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the ‘suboptimal therapy’ patient population

Journal of the Neurological Sciences
Tarunya Arun, Colin Green, Rachael Mccool   +2 more
exaly  

NICE recommends new treatment for highly active relapsing multiple sclerosis

Pharmaceutical Journal
openaire   +1 more source